Recent findings have suggested GAL-201 from Galimedix Therapeutics Inc. is a robust oral candidate to treat Alzheimer’s disease (AD). GAL-201 binds to the misfolded form of amyloid-β (Aβ) monomers, thus preventing its aggregation and formation of neurotoxic oligomers and protofibrils.
Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and affiliated organizations published preclinical data for a new class of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors being developed as candidates for the treatment of lymphoma.
The third day of the AD/PD 2024 conference in Lisbon started with a plenary lecture given by Professor Howard Fillit entitled, “Translating the biology of aging into new therapeutics for Alzheimer’s disease.” Fillit, a recognized neuroscientist and geriatrician, and co-founder of the Alzheimer’s Drug Discovery Foundation (ADDF), pointed to the geroscience hypothesis which postulates that targeting aging processes may result in preventive and therapeutic options for diseases of old age, including Alzheimer’s disease (AD).
Kymera Therapeutics Inc. has described proteolysis targeting chimeras (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2)-targeting moiety through a linker.
Fochon Biosciences Ltd. has divulged apoptosis regulator Bcl-2 (D103E mutant and D103Y mutant) inhibitors reported to be useful for the treatment of autoimmune disease and cancer.
Hotspot Therapeutics Inc. has identified mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.
Mironid Ltd. has synthesized phosphodiesterase PDE4 activators reported to be useful for the treatment cancer, hyperparathyroidism, autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease.
Astrazeneca AB has disclosed myeloperoxidase inhibitors reported to be useful for the treatment of cancer, cardiovascular, inflammatory, renal, neurological and respiratory disorders and liver diseases.
Intermittent fasting (IF) consists of fasting and refeeding cycles that cause dramatic changes in the gut microbiome and microbiota-derived metabolites, subsequently affecting immune response.
Patients with multiple sclerosis have an increased prevalence of sleep disorders compared to the general population, with an estimated rate ranging from 25% to 50% and negative impacts on quality of life.
RSS
